In vitro and in vivo targeting imaging of pancreatic cancer using a Fe 3 
Introduction
Pancreatic cancer is one of the most highly malignant tumors with similar rates of incidence and mortality. Research advances over the past few decades failed to improve the survival rate. The overall 5-year survival rate still remains ,5% since most patients newly diagnosed with pancreatic cancer have already advanced in the disease and are not amenable to surgical therapy. [1] [2] [3] [4] Early and definitive diagnosis and prompt therapy significantly improve the prognosis and increase survival rates. 5 Molecular imaging is a potential way to improve early diagnosis.
Molecular imaging of biological processes in vivo enables the detection of molecular and cellular mutations and the pathological changes at an early stage of the disease and promotes early diagnosis and treatment.
6-8 CA19-9 is a clinical biomarker widely used, but lacks specificity and sensitivity for early diagnosis of pancreatic cancer. 9, 10 Therefore, discovery of highly-specific tumor biomarkers is imperative. Nanomedicine involves application of nanoscience and technology to medicine. Targeted labeling entails combining nanosized materials with biomarkers to synthesize multifunctional
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liu et al complexes and target functional biomarkers to specific cells or tissues in vitro and in vivo.
In recent decades, several serum and tissue biomarkers in pancreatic cancer have demonstrated the benefit of early diagnosis. The high-molecular weight mucins are a family of extracellular proteins that are heavily glycosylated with complex oligosaccharides and play an important role in tumor formation and progression. 11 Mucins 1 and 4 are associated with pancreatic cancer. 12, 13 A study 14 suggest that BxPC-3 and Panc-1 cell lines of pancreatic cancer express mucin 1. They also demonstrated that subcutaneous and orthotopic tumor transplantation emits strong fluorescence signals after injection of fluorophore-conjugated anti-MUC1 antibodies via nude mice tail veins. Wu et al 15 prepared new multifunctional nanoparticles (MnMEIO-silane-NH 2 -[MUC4]-mPEG nanoparticles) containing MUC4 antibodies as a new type of magnetic resonance imaging (MRI) and optical imaging contrast agent. The new type of contrast agent selectively and specifically targeted mucin-expressing tumor tissues in nude mice. Survivin gene, which is a member of the inhibitor of apoptosis family, is abundantly expressed in the serum of most pancreatic cancer patients. 16, 17 Tong et al 18 synthesized a survivin gene-targeted magnetic iron oxide nanoparticle with high stability and without any toxicity. The magnetic molecular probe selectively targeted the pancreatic cancer cells with survivin gene expression. Urokinase plasminogen activator receptor, a cellular receptor, is expressed in .86% of pancreatic cancer tissues, but not in normal or chronic pancreatitis tissues. It also contributes to tumor progression. 19, 20 Studies have shown that urokinase plasminogen activator receptor-targeted nanoparticles selectively accumulate in transplanted tumor lesions of human pancreatic cancer in nude mice. 21 Despite advances involving new biomarkers for pancreatic cancer, none of them has been validated for routine clinical use. Therefore, additional studies have been undertaken to develop or discover specific markers targeting pancreatic cancer and generate novel nanoparticles for clinical use.
Mesothelin (MSLN), which is overexpressed in several tumors, such as mesothelioma, ovarian cancer, and pancreatic cancer, is a 40 kDa cell surface glycoprotein. It is selectively expressed in malignant pancreatic cancer tissue, but not in pancreatic benign tumors, acute or chronic pancreatitis, and normal pancreatic tissues. 22, 23 MSLN plays an important role in the development of pancreatic cancer in different ways. The overexpression of MSLN promotes the motility, increases the proliferation, and inhibits the apoptosis of pancreatic cancer cells, and is associated with tumor invasion and migration. Strong expression of MSLN usually indicates poor prognosis. [24] [25] [26] [27] It is considered as a potential and promising diagnostic, imaging, and therapeutic biomarker in pancreatic cancer. 28 Fe 3 O 4 nanoparticles are the most common superparamagnetic iron oxide components used as multifunctional nanoparticles. Their unique superparamagnetic properties, biocompatibility, and ease of preparation have wide biomedical applications. 29, 30 Silica is a good surface modifier because of its nontoxicity, high stability, water dispersibility, and excellent biocompatibility. 31 It easily facilitates conjugation with various functional groups and enables the coupling and labeling of biological targets with selectivity and specificity. 32 Superparamagnetic iron oxide nanoparticles (SPIONs) covered with silica shells (Fe 3 O 4 @ SiO 2 [FS] ) are potentially the most effective carriers for delivering specific markers and drugs to target sites in the human body. 33 In this study, we synthesized multifunctional nanoprobe FS modified with MSLN antibody. Our team investigated its labeling ability in pancreatic cancer in vitro and in vivo for possible clinical application as a novel molecular probe. 
Materials and methods Materials
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Imaging of pancreatic cancer using an a-MFs nanoprobe cultured at 37°C in a humidified atmosphere containing 5% CO 2 incubator.
Nude mice
Male, 4-to 6-week-old athymic nude mice (BALB/C), weighing 18±2 g, were purchased from the Laboratory Animal Center of the Second Military Medical University, Shanghai, People's Republic of China, and raised under specific pathogen-free conditions at a constant temperature of 25°C-27°C and humidity of 40%-50%. The animal experiments were approved and performed in accordance with the guidelines of the Animal Pro tection and Care Committee of the Second Military Medical University. The number of animal ethics is 13071002132.
Preparation of pancreas cancer xenografts
The density of logarithmic phase SW1990 cell suspension was adjusted to 2×10 7 /mL with PBS. An amount of 0.1 mL of the cell suspension was injected subcutaneously, respectively, into the right axillas of nude mice. These mice continued to be raised under specific pathogen-free conditions in the Laboratory Animal Center.
Preparation of nanoprobe Fe 3 O 4 (nanoparticles)
The magnetic microspheres were prepared by a solvothermal reaction. 34 Using 2.56 g of sodium acetate and 0.86 g of FeCl 3 ⋅6H 2 O dissolved in 30 mL of ethylene glycol under vigorous magnetic stirring. The homogeneous yellow solution was transferred to Teflon-lined stainless-steel autoclave and heated at 200°C for nearly 8 hours, and cooled to room temperature. Each of the products was washed three times with ethanol and DI water and redispersed into DI water for use.
Preparation of the Fs-Nh 2 probe
An aqueous dispersion of 5 mL of Fe 3 O 4 (50 mg/mL) was treated with 0.1 M HCl aqueous solution under sonication for 15 minutes. The treated Fe 3 O 4 microspheres were dispersed in a mixture of ethanol and water (v/v=70/30) briefly. The pH was adjusted to ~9.5 by addition of ammonium hydroxide. Later, 80 μL of tetraethylorthosilicate was poured into the reactor with vigorous stirring at room temperature for ~24 hours. To graft amino groups, 35 50 mL (3-aminopropyl)triethoxysilane was injected into the system under stirring for 4 hours. Methanol was then added to precipitate the product. Following centrifugation, the product was washed with ethanol several times, and finally dispersed in deionized water.
Synthesis of FS probe modified with anti-MslN antibody
The amino-silane-coated magnetite particles were mixed with PEG diacid solution (molecular weight, 6,000) in the ratio of 1:2, followed by the addition of 5 mg of EDC⋅HCl to the solution. The solution was stirred overnight at room temperature. The resulting product (FS/PEG) was purified by ethanol and DI water, each three times, and redispersed into borate saline buffer (50 mM, pH 8.2) for conjugation with anti-MSLN antibody using EDC⋅HCl as the cross-linker. The FS/PEG was reacted with nanoparticles:anti-MSLN antibody:EDC⋅HCl in the molar ratio of 1:10:4,000 in a borate saline buffer (50 mM, pH 8.2) under continuous stirring for 2 hours at room temperature. The final bioconjugates were dispersed in PBS (0.01 M, pH 7.4, 0.5% bovine serum albumin, 0.02% sodium azide) after magnetic separation and washed with 0.01 M PBS (pH 7.4) twice.
characterization of a-MFs
The morphology of the material was observed by transmission electron microscopy using a JEM-2100F electron microscope (JEOL Ltd., Tokyo, Japan), and its hydrodynamic diameter was measured by nanoparticle size analyzer (NanoZS90). The stability test of A-MFS can be found in the Supplementary Materials. The longitudinal (T1) and transverse (T2) relaxation times of A-MFS were measured with a 1.41 T minispec mq 60 NMR Analyzer (Bruker, Karlsruhe, Germany) at 37°C. Relaxivity values of r1 and r2 were calculated by fitting the 1/T1 and 1/T2 relaxation time (s −1 ) versus Fe concentration (mM) curves. X-ray photoelectron spectroscopy was used to detect chemical elements of A-MFS.
cell toxicity
The cytotoxicity of the nanoprobe FS modified with anti-MSLN antibody against human pancreatic cancer SW1990 cells was determined by measuring the inhibition of the cell growth using a CCK-8 assay. SW1990 cells were first seeded in a 96-well plate at a density of 5,000 cells/well and incubated overnight at 37°C and 5% CO 2 in an incubator. Next, three wells of SW1990 cells were incubated with various concentrations of magnetic vesicles (0, 100, 200, 300, 400, and 500 mg/L) for 2, 6, and 24 hours, respectively. Each well was then supplemented with 10 μL CCK solution, followed by incubation of the culture plate for 1 to 4 hours. Eventually, the absorbance at 450 nm was measured using a microplate reader to determine the number of live cells indirectly. The cell viability was measured by calculating the amount of formazan dye generated by the activity of cellular dehydrogenases, which was directly proportional to the number of living cells.
In vitro targeting
Pancreatic cancer cell line SW1990 supplied by the Department of Digestive Diseases of Changhai Hospital (Shanghai, People's Republic of China) was cultured. In order to test the targeting ability of the A-MFS with SW1990 cells in vitro, red fluorescence quantum dots, which are water-soluble, were added to both the probes FS and A-MFS to synthesize fluorescence nanomaterials. The SW1990 cells in the logarithmic phase were incubated with 5 μL of fluorescent nanoprobes (1 mg/mL) FS and A-MFS, respectively, for 30 minutes. LM-3, a human liver cancer cell line, was provided by The Institute for Biomedical Engineering and Nano Science at Tongji University School of Medicine, Shanghai, People's Republic of China. LM-3 cells in the logarithmic phase were also incubated with 5 μL of fluorescent nanoprobe A-MFS (1 mg/mL) for 30 minutes. After incubation, cells in the three groups were visualized through fluorescence microscope to determine the different effects of FS and A-MFS on SW1990 and LM-3 cells.
The SW1990 and LM-3 cells were digested with pancreatin, and the supernatant was discarded after centrifugation. The sample was analyzed by flow cytometry, after cells were washed with 300 μL PBS.
In vivo MrI
In this study, all the mice were successfully developed into subcutaneously transplanted tumor models. When the diameter of subcutaneously transplanted tumor reached 1.0 cm, nine mice were divided into three groups randomly. The control group of mice received an intravenous injection of 0.1 mL saline solution via caudal veins. The other two groups were injected with 1 mg/mL of FS and A-MFS solution (0.1 mL per mouse), respectively, via caudal veins. All the images of mice were obtained using Siemens 3.0 T magnetic resonance scanner. Before MRI imaging, 1% pentobarbital sodium (75 mL/kg) was injected into the abdominal cavity to ensure that the mice were anesthetized. Mouse limbs were fixed by adhesive tape on hardboard and replaced into the finger coil. Images were obtained before and after 30 minutes, 1, 2, 2.5, and 3 hours following intravenous injection of the solution, respectively. The MRI scan range exceeded the tumor size. T2WI axial and coronal images of fast spin echo were captured at each phase. Specific imaging parameters were as follows: T2-weighted fast echo-spin axial of field of view =60×48.8 mm, slice thickness =2 mm, repetition time =3,500 ms, echo time =92 ms, resolution ratio =192×192, voxel size =0.3×0.3×2.0 mm; the T2-weighted fast echo-spin coronal of field of view =80×65 mm, slice thickness =2 mm, repetition time =3,500 ms, echo time =92 ms, resolution ratio =192×192, and voxel size =0.4×0.4×2.0 mm. We selected the regions of interest measuring 2 mm 2 on the tumor solid component of each phase to measure signal values, after all the images were captured.
Test of Fe distribution in vivo
The organs and tissues, including liver, spleen, kidney, heart, lung, and tumor were collected from the anesthetized mice ~2.5 hours after injection with FS or A-MFS. They were eroded with concentrated nitric acid to determine the biodistribution of Fe using inductively coupled plasma-atomic emission spectrometry.
histochemistry
Following MR scanning, two mice from control and experimental groups were killed by cervical dislocation at an appropriate time. Heart, liver, spleen, lung, and kidney were removed to obtain routine paraffin sections. These tissues were embedded in 10% buffered formaldehyde, followed by paraffin for hematoxylin and eosin staining to observe the pathological changes in the organs of the two groups. An experienced pathologist with .5 years of experience reviewed the microscopic images of the tissues.
Transmission electron microscopy
Mice in the experimental group injected with A-MFS were dissected after in vivo MRI. Tumor tissue was then cut into ultrathin sections and observed under a transmission electron microscope.
statistical analysis
The signal values were recorded as mean ± standard. Student's unpaired t-test was used to analyze the differences between experimental and control groups. A P-value below 0.05 was considered statistically significant.
Results
characterization of the nanoprobe
The procedure outlining construction of FS modified with anti-MSLN antibodies is shown in Figure 1 . The morphological structure of the probe, the distribution of hydrodynamic diameters relaxation rate, and X-ray photoelectron spectroscopy results are shown in Figure 2 . The probe FS modified with anti-MSLN antibodies is spherical and regular in shape.
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Imaging of pancreatic cancer using an a-MFs nanoprobe The black central portion of the probe is the magnetic nucleus, with a larger electron density. The surrounding gray portion is the amorphous SiO 2 wrap. The size of the probe particle is uniform, and most of the hydrodynamic diameters range between 110 and 130 nm. The T2 relaxation rate of A-MFS is 59.435 mM/s and its T1 relaxation rate is 0.549 mM/s. Its relaxation rate is similar to others in the literature. 28 It means A-MFS can be used as negative contrast material. A-MFS has good stability of dispersion as shown in Figure S1 . X-ray photoelectron spectroscopy detected that A-MFS contain Fe, O, C, N, and Si, so the result shows Si and antibodies are coated on the nanoparticle. Fe 3 O 4 and SPIONs are most commonly used for preparation of multifunctional nanoparticles due to their unique superparamagnetic features, high stability, and biocompatibility. The superparamagnetic behavior of SPIONs is essential for MRI. Each SPION acts as a small magnet; therefore, SPIONs display increased magnetization and respond rapidly to external magnetic field. After removing the external magnetic field, magnetized nanoparticles are dissipated by a brief shaking. SPIONs shorten the tissue T2-weighted relaxation time to enhance tissue MRI contrast and, therefore, are widely used as T2 contrast agents. The high stability of SPIONs enables persistent circulation in the blood and accumulation in the target area. If the probe diameter exceeds 300 nm, they are phagocytosed by the reticuloendothelial system. They persist in the blood circulation and accumulate less in tissues. Silica is used as a surface modifier of nanoparticles due to its nontoxicity and stability. Fe 3 O 4 is sealed by SiO 2 coating to improve its biocompatibility. The silica coating provides binding sites for the anti-MSLN antibody. Therefore, our team successfully synthesized the A-MFS probe with good magnetic properties and high stability.
cytotoxicity of a-MFs
The cytotoxicity of FS modified with anti-MSLN antibody in SW1990 cells was determined using a CCK-8 assay. SW1990 cells were incubated with different concentrations (0, 100, 200, 300, 400, and 500 mg/L) of the target nanoprobe solutions. The CCK-8 assay showed that the A-MFS had dose-dependent cytotoxicity for SW1990 cells. As shown in Figure 3 , with the increase in the concentration of A-MFS, the cell viability was above 86%, irrespective of the incubation period (2, 6, and 24 hours). The cell viability was higher than 95%, when the concentration of the probe was under 400 mg/L. In this study, the concentration of the probe was 1 mg/mL. Therefore, A-MFS was almost noncytotoxic, with potential biomedical applications. Fe is an essential element for human body; for example, it mediates the formation of hemoglobin and myohemoglobin and also associates with the activity of specific enzymes in vivo. Therefore, SPIONs, including Fe 3 O 4 , are considered as safe contrast agents for imaging applications as they can be reduced to iron, which eventually contributes to the normal iron levels. The safety of silica is proven. In our study, A-MFS showed limited cytotoxicity and, therefore, is used in in vitro and in vivo studies. 
In vitro targeting test
In vivo targeting by a-MFs
The in vivo MRI was successfully completed. The MRI T2-weighted images of nude mice are shown in Figure 6 , and the quantitative tumor signal values are shown in Figure 7 . 
2201
Imaging of pancreatic cancer using an a-MFs nanoprobe 
2203
Imaging of pancreatic cancer using an a-MFs nanoprobe
The T2 signal values of experimental group xenograft were decreased by 342.533±42.6 after injection of the target probe, and the control group was decreased by −61.233±33.9 after injection of saline solution, while the FS group decreased by −58.7±19.4 at 2.5 hours. The decrease of tumor signal by A-MFS was much more significant than that by saline and FS (P,0.05). Results could be seen in Figures S2 and S3 . Similarly, the T2-weighted images showed that the tumor signal in the experimental group was decreased after injection of the probe FS modified with anti-MSLN antibody, while the control and FS groups were barely altered. Due to its paramagnetic properties, Fe 3 O 4 acts as a negative contrast agent of MRI. It decreases the T2-weighted tissue signal to enhance the contrast by shortening the transverse relaxation time T2, suggesting that the nanoprobe selectively accumulated in the pancreatic cancer tissue, shortened the transverse relaxation time, and decreased signal of tissue. Therefore, FS modified with anti-MSLN antibody is a good T2 targeting agent in pancreatic cancer of nude mice. It may also be a promising and potential agent for clinical diagnosis of pancreatic cancer.
Fe distribution in organs
The distribution of Fe in vivo in mice injected with FS and A-MFS is illustrated in Figure 8 . The Fe levels in the tumors of A-MFS group were obviously higher than in the FS group. The Fe levels in the lung were also increased. The Fe in other organs (heart, liver, spleen, and kidney) was approximately similar in A-MFS and FS groups. The xenografts of pancreatic cancer express higher MSLN levels than the other organs. MSLN is normally present on the mesothelial lining of the pleura. The visceral pleura cover the lung closely and directly and cannot be removed during the lung extraction. The results demonstrate that the probe FS modified with anti-MSLN antibody selectively accumulates in transplanted pancreatic cancer and pleural mesothelial cells. Both results showed that the probe targeted MSLN-expressing tissues and demonstrated effective in vivo targeting potential of A-MFS.
Pathology
Comparative histochemical analysis following hematoxylin and eosin staining of organs in the experimental (A-MFS) and control (saline solution) group mice is presented in Figure 9 . The maps show no significant differences in histology between the two sets. Therefore, the targeting nanoparticle was completely nontoxic to mice and suggests potential for clinical application.
Transmission electron microscopy
As shown in Figure 10 , the transmission electron microscopy of transplanted tumors treated with A-MFS revealed A-MFS accumulation in the tumor cells. 
Conclusion
In this study, the FS probe was successfully prepared and coloaded with anti-MSLN antibody. Results showed stable and nontoxic A-MFS with regular morphology. Targeting a nanoprobe to the MSLN antigen is an effective contrast agent in pancreatic cancer cells. Our team demonstrated that A-MFS was capable of specifically recognizing the MSLNexpressing cells in vitro. In addition, A-MFS also exhibits excellent MRI properties and targeting potential to human pancreatic cancer xenografts in nude mice in vivo. Therefore, A-MFS effectively targets pancreatic cancer in vitro and in vivo. In conclusion, A-MFS represents a potential T2 contrast agent for the diagnosis of pancreatic cancer, and it will also be beneficial to find its metastasis. 
Supplementary materials stability of dispersion test
In order to observe the stability of A-MFS in solution, different concentrations of A-MFS solutions (50 mg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL) were rested at room temperature for different times (0, 4, 24 hours). The optical images were taken to reflect their stability. Results show that the nanoparticle has a good dispersion at macro level, as shown in Figure S1 .
In vivo MrI test of Fs
Three mice were injected with 1 mg/mL of Fe 3 O 4 @SiO 2 (FS) (0.1 mL per mouse), respectively, via caudal veins. All the images of mice were obtained using 
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